NeurologyLive® Friday 5 — January 28, 2022

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 28, 2022.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Demystifying Multiple Sclerosis Etiology: The Role of Epstein Barr Virus

This expert-led panel discussion, moderated by Scott Newsome, DO, will review new findings showing a significant and causative relationship between infection with Epstein Barr virus and the development of multiple sclerosis, and discuss the implications for patients, the health care providers who treat them, and the greater neurology community.

2: How MR Fingerprinting Can Improve Epilepsy Surgery: Irene Wang, PhD

The research director and staff scientist at Cleveland Clinic’s Epilepsy Center detailed the clinical pre- and post-surgery benefits patients with epilepsy get from MR fingerprinting, a novel technology that uses conventional MRI scanners but can quantify multiple properties of tissue in a single scan, characterizing areas smaller than a single voxel in a fraction of the time.

3: NeuroVoices: Joanna Hellmuth, MD, MS, on Recognizing, Characterizing Post-COVID Cognitive Changes

The cognitive neurologist at the University of California, San Francisco discussed recently published data on the presence of cognitive post-acute sequelae of COVID-19, the need to legitimize these conditions, the hypothesis that understanding the clinical features associated with cognitive PASC may inform groups at greater risk and highlight possible underlying mechanisms.

4: Podcast Episode 56: Epstein-Barr Virus's Relationship With Multiple Sclerosis

Mind Moments™, a podcast from NeurologyLive®, brings you an exclusive interview with Bridget A. Bagert, MD, MPH, director, Ochsner Multiple Sclerosis Center, and an investigator in the clinical study of an Epstein-Barr virus-targeted agent, ATA188 (Atara Biotherapeutics).

5: Diverse Enrollment, Primary End Point Announced for Phase 4 ENVISION Study of Aducanumab

Biogen and Eisai announced an increase in enrollment to 1500, and that 18% percent of the Alzheimer disease treatment’s study participants are anticipated to be Black/African American and Latinx.

—————————————————
LAST CALL: Giants of Multiple Sclerosis™

Recognize and celebrate the individuals who have achieved landmark successes within multiple sclerosis! Giants of Multiple Sclerosis™ is a premier neuroscience award that celebrates pioneers, innovators, and future generations of leaders who have been selected by their peers for their remarkable achievements in Multiple Sclerosis.

Nominate Someone Today for a 2022 Giants of Multiple Sclerosis™ Award

  • Nominations are open through January 31, 2022
  • The Giants of Multiple Sclerosis™ Steering Committee will vet all nominations and vote to determine the 2022 inductees
  • Nominees will be selected on the merits of their lifetime work.
  • One honoree in each category who makes a measurable difference in the lives of patients will be awarded.
  • The 2022 Giants of Multiple Sclerosis™ inaugural class will be announced in Spring of 2022

Nominate someone here.